NDC 67296-2191-01 - BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 67296-2191
- Requested NDC
- 67296-2191-01
- Package NDCs from labels
- 67296-2191-1, 67296-2191-6, 67296-2191-01
- Manufacturer
- Redpharm Drug
- Effective date
- 2026-01-23
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE - Redpharm Drug | Redpharm Drug | 2026-01-23 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67296-2191-1 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 12 in 1 BOTTLE, PLASTIC | TABLET | 12 | 2 | |
| 67296-2191-6 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 6 in 1 BOTTLE, PLASTIC | TABLET | 6 | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Buprenorphine and Naloxone | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | d5b011ef-f1be-47f2-8f8b-07553f36193c | 2026-02-28 | Warnings, Adverse reactions | 351266 351267 56W8MW3EN1 |
| Kidnex IV | GINKGO BILOBA, ALPHA-KETOGLUTARICUM ACIDUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MALICUM ACIDUM, PYRUVIC ACID, SUCCINICUM ACIDUM, ARGENTUM METALLICUM, AURUM METALLICUM, CUPRUM METALLICUM, GERMANIUM SESQUIOXIDE, MERCURIUS VIVUS, NUX VOMICA, KIDNEY (SUIS), LYMPH NODE (SUIS), NAPHTHOCHINONUM, NATRUM OXALACETICUM, PHOSPHORUS, URINARY BLADDER (SUIS), ACONITICUM ACIDUM, CIS- | Energique, Inc. | 23de6b8e-7622-4ba6-89f7-37bd151687e2 | 2026-02-26 | Warnings | XF417D3PSL |
| Tricitrates | TRICITRATES | Chartwell Governmental & Specialty RX, LLC. | c4ff0407-3930-4c48-afd4-d2cb3e1b18f4 | 2026-02-25 | Warnings, Adverse reactions | 1Q73Q2JULR |
| Leader Extra Strength Effervescent Antacid and Pain Reliever | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Cardinal Health | c5d7bf5f-3e59-52f2-e053-2a95a90a4a00 | 2026-02-25 | Warnings | XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 300ae3d0-464c-d0be-e063-6294a90a7f9d | 2026-02-21 | Warnings, Adverse reactions | 5Q187997EE 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Unit Dose Solutions, Inc. | 4b301ad7-ac0e-f849-e063-6394a90a27d5 | 2026-02-19 | Warnings, Adverse reactions | 351267 5Q187997EE 56W8MW3EN1 |
| Mitochondria Pro | ARALIA QUINQUEFOLIA, ARNICA MONTANA, ADENOSINUM TRIPHOSPHORICUM DINATRUM, ALPHA-KETOGLUTARICUM ACIDUM, ASCORBICUM ACIDUM, ALPHA-LIPOICUM ACIDUM, CALCAREA CARBONICA, CITRICUM ACIDUM, CUPRUM METALLICUM, CYSTEINUM, FERRUM METALLICUM, IODIUM, LEVOTHYROXINUM, MAGNESIUM GLUCONICUM DIHYDRICUM, MALICUM ACIDUM, MANGANUM ACETICUM, NADIDUM, NATRUM PYRUVICUM, NICOTINAMIDUM, PYRIDOXINUM HYDROCHLORICUM, RIBOFLAVINUM, SELENIUM METALLICUM, SULPHUR, THIAMINUM HYDROCHLORICUM, UBIDECARENONUM, ZINCUM METALLICUM, | Energique, Inc. | 2f365207-b730-428d-9465-8853e86e79ff | 2026-02-18 | Warnings | XF417D3PSL |
| Buprenorphine | BUPRENORPHINE | Sun Pharmaceutical Industries, Inc. | 9fd1f18f-0b0f-4059-b603-19ecbf0ed63a | 2026-02-11 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Sun Pharmaceutical Industries, Inc. | 91b68606-05de-4586-ae31-07e8cc9160cf | 2026-02-10 | Warnings, Adverse reactions | 351266 351267 5Q187997EE 56W8MW3EN1 |
| GoodSense Eye Drops Advanced Relief Moisturizer | DEXTRAN, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HCL | Sportpharm LLC | 8d58dcbb-72a0-41f0-9eeb-613072a6d7ae | 2026-02-06 | Warnings | FZ989GH94E |
| BUPRENORPHINE | BUPRENORPHINE | A-S Medication Solutions | bfb02ea5-22f2-432e-afc8-f1dbe2ea0614 | 2026-02-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Actavis Pharma, Inc. | 6cccf229-9611-4b6f-8f1b-acc8ff1ed3f8 | 2026-02-06 | Warnings, Adverse reactions | 351266 351267 5Q187997EE 56W8MW3EN1 |
| MINIDROPS | LUBRICANT EYE DROPS | Optics Laboratory, Inc | c13c5f91-50df-471c-a7c9-1747a2ac1250 | 2026-02-03 | Warnings | FZ989GH94E |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Amneal Pharmaceuticals LLC | 17b63f10-c9df-44be-80fa-6f1c305583b8 | 2026-02-02 | Warnings, Adverse reactions | 351266 351267 5Q187997EE 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Camber Pharmaceuticals, Inc. | 221195e4-de08-414c-af08-a611a74789de | 2026-01-30 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Lannett Company, Inc. | 14eaa94a-cc8a-4e1e-8cfb-5c976c96c606 | 2026-01-28 | Warnings, Adverse reactions | 351266 351267 |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID MONOHYDRATE | Atlantic Biologicals Corp. | 42d837ae-2578-46df-92d2-24774964aaad | 2026-01-28 | Adverse reactions | 1Q73Q2JULR XF417D3PSL |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Camber Pharmaceuticals, Inc. | 5ab2d4e4-3c8c-413a-b147-23eafbde313a | 2026-01-28 | Warnings, Adverse reactions | 351266 351267 5Q187997EE 56W8MW3EN1 |
| Buprenorphine | BUPRENORPHINE | Hikma Pharmaceuticals USA Inc. | 1bf8b35a-b769-465c-a2f8-099868dfcd2f | 2026-01-24 | Warnings, Adverse reactions | 56W8MW3EN1 |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Redpharm Drug | 44f2e26f-4586-5204-e063-6394a90a47d5 | 2026-01-23 | Warnings, Adverse reactions | ANDA209069 67296-2191-6 67296-2191-1 67296-2191 67296219101 351267 490df063-a9d0-7d96-e063-6394a90a1e15 44f2e26f-4586-5204-e063-6394a90a47d5 5Q187997EE 56W8MW3EN1 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.